AustralianSuper Pty Ltd Has $10.04 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

AustralianSuper Pty Ltd raised its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 12.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,029 shares of the biotechnology company's stock after buying an additional 2,998 shares during the quarter. AustralianSuper Pty Ltd owned about 0.06% of United Therapeutics worth $10,044,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. ClariVest Asset Management LLC grew its position in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at approximately $30,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at approximately $33,000. USA Financial Formulas acquired a new position in shares of United Therapeutics in the 3rd quarter valued at approximately $33,000. Finally, Values First Advisors Inc. acquired a new position in shares of United Therapeutics in the 3rd quarter valued at approximately $90,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

United Therapeutics stock traded up $12.57 during mid-day trading on Thursday, hitting $373.97. 585,359 shares of the company's stock traded hands, compared to its average volume of 466,846. The firm has a 50 day simple moving average of $354.88 and a two-hundred day simple moving average of $315.69. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $377.03. The stock has a market cap of $16.59 billion, a price-to-earnings ratio of 17.68, a P/E/G ratio of 1.27 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter last year, the firm posted $5.38 EPS. The company's quarterly revenue was up 22.9% on a year-over-year basis. On average, research analysts expect that United Therapeutics Co. will post 24.72 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,785 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now owns 2,615 shares in the company, valued at $947,597.55. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other United Therapeutics news, CFO James Edgemond sold 7,785 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now owns 2,615 shares in the company, valued at $947,597.55. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm's stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $324.73, for a total value of $1,169,028.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $42,214.90. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 107,012 shares of company stock valued at $36,767,286 in the last quarter. 12.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research report on Thursday. TD Cowen boosted their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Bank of America cut their target price on United Therapeutics from $303.00 to $280.00 and set an "underperform" rating on the stock in a research note on Thursday, August 1st. Finally, Wells Fargo & Company boosted their target price on United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a research note on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $366.43.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.